What is the significance of Elanco Animal Health Inc.’s ranking on the list of cheap stocks under $10? How does Tom Lee’s perspective on market uncertainty influence investor behavior? Why are hedge fund interests considered valuable indicators for stock selection? What growth factors contributed to Elanco’s revenue increase in its International Pet Health segment? How does Elanco’s product portfolio affect its market presence in the animal health industry? What potential does Tom Lee see for Bitcoin in relation to its previous high? What are the implications of selecting stocks based on enduring investment themes as described by Tom Lee?
We recently published a list of the 10 Best Cheap Stocks to Buy Under $10. In this article, we are going to take a look at where Elanco Animal Health Inc. (NYSE:ELAN) stands against other cheap stocks to buy under $10. On April 21, Tom Lee, Fundstrat CIO, co-founder, and managing partner, joined ‘Squawk Box’ on CNBC to discuss the latest market trends and stated that the market may be past peak uncertainty despite the ongoing Fed uncertainties. However, Lee thinks that ‘maximum pain’ can still be anticipated, as economic risks could still cause hesitation among investors. Despite this, he believes that a structural low in fear has taken place. He acknowledged that the last low at the S&P 500 was around 4,800, which was reached a few weeks prior, and he thinks that there is a chance the market could drift dangerously close to that level in the coming weeks due to the ongoing uncertainty and investors remaining on the sidelines. Nevertheless, Lee emphasized that companies are very resilient, which should become evident during earnings season. He also mentioned the potential for a positive policy shock, such as a reduction in tariffs or de-escalation in trade tensions with countries like China, which could be seen as a win by the market, even though such developments did not seem likely overnight.
Lee also elaborated on his ‘Granny Shot’ ETF, and mentioned that the granny shots in their portfolio are stocks that, while not immune to declines, are closely linked to the most important long-term investment themes, such as cybersecurity and demographic shifts, such as the rise of millennials. The idea is to select stocks that are strongly correlated with multiple enduring themes, which increases the chances that these stocks will perform well over time, likening this to the reliability of a well-executed granny shot in basketball. Lee also noted that Bitcoin may have been held back by institutional deleveraging earlier this year, with investors selling what they could, which suppressed Bitcoin’s price, but that deleveraging process appears to be over. He now expects Bitcoin to catch up to gold and highlighted that Bitcoin’s previous high was over $110,000, which suggests that there is room for Bitcoin to appreciate as it regains momentum as a non-dollar asset. Gold recently surged to new highs, seemingly on track to reach $4,000, while Bitcoin was lagging, but it would eventually attract some of the same investment flows that were driving gold higher.
We first used the Finviz stock screener to compile a list of cheap stocks that had a forward P/E ratio under 15 and were trading under $10. We then selected the 10 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey’s database which tracks the moves of over 1000 elite money managers.
Note: All data was sourced on April 22.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Is Elanco Animal Health Inc. (NYSE:ELAN) the Best Cheap Stock to Buy Under $10?
A farmer tending to a herd of cattle with Innovative Parasiticide and Vaccine Products.
Share Price as of April 22: $8.48
Forward P/E Ratio as of April 22: 10.07
Number of Hedge Fund Holders: 37
Elanco Animal Health Inc. (NYSE:ELAN) is an animal health company that innovates, develops, and manufactures products for pets and farm animals. It offers pet health products and therapeutics under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks. It sells its products to third-party distributors and independent retailers, and directly to farm animal producers and veterinarians.
In Q4 2024, the company’s International Pet Health segment surged with an 11% increase in organic constant currency revenue. This growth primarily came from two key products: AdTab and Seresto. AdTab is a flea and tick protection product for both dogs and cats. It uses the same active ingredient as Credelio, which is growing through Elanco’s DTC strategies in Europe. This has led Elanco to revise its sales expectation for AdTab, now projecting it to exceed $100 million.
Seresto is also a flea and tick collar that provides long-lasting protection, typically around 8 months. The growth within this segment was widespread across Europe, the Middle East, Latin America, Asia Pacific, and Canada. Elanco anticipates an acceleration in its organic constant currency revenue growth to 4% to 6% for the full year 2025, driven by the strong momentum in International Pet Health.
Overall, ELAN ranks 10th on our list of the best cheap stocks to buy under $10. While we acknowledge the growth potential of ELAN, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ELAN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Is Elanco Animal Health Inc. (NYSE: ELAN) the Best Cheap Stock to Buy Under $10?
In the swirling world of stock market investment, identifying cheap, promising stocks can often seem like searching for a needle in a haystack. Among the plethora of choices, Elanco Animal Health Inc. (NYSE: ELAN) has been making headlines as a potential bargain buy under the $10 mark. But does it really hold the title of "the best cheap stock to buy"? To answer that question, we’ll delve into Elanco’s business model, financial health, market positioning, and the broader economic indicators that may affect its share price.
Company Overview
Elanco Animal Health is a renowned name in the veterinary pharmaceuticals industry, primarily involved in the development and manufacturing of products for both livestock and companion animals. It offers a wide range of solutions, from vaccines and anti-infectives to parasiticides and nutritional products. Since its IPO in 2018, the company has aimed to leverage the growing demand for animal health products driven by increasing pet ownership, intensified livestock farming, and consumer consciousness about healthy food sources.
Current Financial Performance
As of the latest quarter, Elanco’s financial metrics show a mix of strengths and weaknesses. The company has faced some challenges, including fluctuating revenue and profitability pressures. For instance, in its fiscal year 2022, Elanco reported revenues of approximately $4 billion, which illustrated a moderate growth trajectory but fell short of investor expectations.
Despite these challenges, Elanco maintains a solid market share in the animal health sector. Analysts have noted operational efficiencies generated through cost-reduction strategies, which could fuel margin improvements over time. Furthermore, Elanco’s commitment to innovation — with a steady pipeline of new product launches — indicates potential for revenue growth in the coming quarters.
Valuation Considerations
One of the compelling reasons to consider Elanco a cheap stock is its current valuation metrics. When analyzing price-to-earnings (P/E) ratios, Elanco’s figures compare favorably, especially against the backdrop of broader market valuations. A stock trading under $10 can often pique investor interest as it may indicate an undervalued opportunity, particularly if the business fundamentals show potential for growth.
However, it’s crucial to dig deeper than the surface-level metrics. Evaluating the company’s enterprise value (EV), price-to-sales (P/S) ratios, and debt-to-equity (D/E) ratios can provide a more comprehensive view of its financial health. Elanco’s D/E ratio has raised concerns among some analysts, signaling potential leverage risks. Thus, even as a cheap stock, investors should exercise caution and assess these financial elements carefully.
Market Position and Competitive Landscape
Elanco operates in a competitive landscape with major players like Zoetis Inc. and Merck Animal Health. These incumbents have established robust portfolios and global distribution networks, posing a challenge for Elanco in terms of market share and pricing. Still, Elanco has carved out a niche, especially in the companion animal segment, where pet healthcare remains a priority for many consumers.
The company’s focus on digital transformation and customer engagement to better understand market demands positions it favorably moving forward. This strategy is critical as the landscape of the animal health industry is changing rapidly, with consumers becoming increasingly reliant on technology for health advice and product purchasing. Elanco’s innovative approach could give it a competitive edge over traditional players.
Broader Economic Indicators
Investing in a stock like Elanco also demands an awareness of broader economic trends. The animal health market tends to be somewhat counter-cyclical, showing resilience during economic downturns, as pet owners typically prioritize the well-being of their animals. Moreover, the increasing demand for sustainable animal farming practices supports the long-term growth potential of companies like Elanco.
However, macroeconomic factors such as inflation, interest rates, and supply chain disruptions can influence Elanco’s operational costs and, consequently, profitability. If inflation persists, costs for raw materials and operating expenses could squeeze margins unless effectively managed.
Is ELAN the Best Cheap Stock?
In conclusion, calling Elanco Animal Health Inc. the best cheap stock under $10 requires a careful balancing act. It showcases promising aspects such as a solid market position and a commitment to innovation that could drive future growth. However, it also demonstrates vulnerabilities regarding debt levels and competitive positioning. While it presents an intriguing opportunity, potential investors must conduct thorough research, assess their risk tolerance, and keep an eye on broader economic trends.
Ultimately, Elanco’s stock price may present a value opportunity, but prudent investment decisions always involve careful consideration of both potential rewards and risks. As Elanco continues to navigate a rapidly changing industry, keeping abreast of its developments will be crucial for any investor looking to capitalize on this animal health player’s journey.
When considering whether Elanco Animal Health Inc. (NYSE: ELAN) is a good investment opportunity under $10, it’s crucial to evaluate several factors:
Financial Performance: Examine the company’s recent earnings reports, revenue growth, and profit margins. Look for trends in financial health and performance metrics.
Market Position: Assess Elanco’s position in the animal health industry, including its competitive advantages, market share, and product portfolio.
Valuation Metrics: Analyze valuation ratios such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B) to determine if the stock is undervalued compared to its peers.
Growth Potential: Consider the company’s growth prospects, including new product launches, expanding markets, and overall industry trends affecting demand for animal health products.
Risks: Identify potential risks, including regulatory challenges, competition, and market volatility, that could impact the company’s performance and stock price.
- Analyst Opinions: Look at analysts’ ratings and target prices for Elanco to gauge market sentiment and expert outlook.
Conducting thorough research on these aspects will provide a clearer picture of whether Elanco is a worthwhile investment under $10. Keep in mind that stock investments often carry risks, and it’s essential to align them with your financial goals and risk tolerance.